| The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor–mediated cross-linking MB Overdijk, JH Jansen, M Nederend, JJ Lammerts van Bueren, ... The Journal of Immunology 197 (3), 807-813, 2016 | 301 | 2016 |
| Glutaminyl cyclase is an enzymatic modifier of the CD47-SIRPα axis and a target for cancer immunotherapy MEW Logtenberg, JHM Jansen, M Raaben, M Toebes, K Franke, ... Nature medicine 25 (4), 612-619, 2019 | 184 | 2019 |
| In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling S de Haij, JHM Jansen, P Boross, FJ Beurskens, JE Bakema, DL Bos, ... Cancer research 70 (8), 3209-3217, 2010 | 157 | 2010 |
| The high-affinity IgG receptor, FcγRI, plays a central role in antibody therapy of experimental melanoma L Bevaart, MJH Jansen, MJ van Vugt, JS Verbeek, JGJ van de Winkel, ... Cancer research 66 (3), 1261-1264, 2006 | 142 | 2006 |
| IgA EGFR antibodies mediate tumour killing in vivo P Boross, S Lohse, M Nederend, JHM Jansen, G van Tetering, M Dechant, ... EMBO molecular medicine 5 (8), 1213-1226, 2013 | 130 | 2013 |
| Potent Fc receptor signaling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG AM Brandsma, S Bondza, M Evers, R Koutstaal, M Nederend, ... Frontiers in immunology 10, 704, 2019 | 126 | 2019 |
| CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations HH van Ojik, L Bevaart, CE Dahle, A Bakker, MJH Jansen, MJ van Vugt, ... Cancer research 63 (17), 5595-5600, 2003 | 112 | 2003 |
| The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden P Boross, JHM Jansen, S de Haij, FJ Beurskens, CE van der Poel, ... haematologica 96 (12), 1822, 2011 | 85 | 2011 |
| Mac-1 (CD11b/CD18) is crucial for effective Fc receptor–mediated immunity to melanoma AB van Spriel, HH van Ojik, A Bakker, MJH Jansen, JGJ van de Winkel Blood, The Journal of the American Society of Hematology 101 (1), 253-258, 2003 | 84 | 2003 |
| IgA-mediated killing of tumor cells by neutrophils is enhanced by CD47–SIRPα checkpoint inhibition LW Treffers, T Ten Broeke, T Rösner, JHM Jansen, M van Houdt, S Kahle, ... Cancer immunology research 8 (1), 120-130, 2020 | 76 | 2020 |
| Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. JHM Jansen, P Boross, MB Overdijk, JJL van Bueren, PWHI Parren, ... Blood, The Journal of the American Society of Hematology 120 (21), 2974-2974, 2012 | 73 | 2012 |
| An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo S Lohse, S Meyer, LAPM Meulenbroek, JHM Jansen, M Nederend, ... Cancer research 76 (2), 403-417, 2016 | 69 | 2016 |
| MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL IB Vikström, A Slomp, EM Carrington, LM Moesbergen, C Chang, GL Kelly, ... Cell death & disease 7 (8), e2345-e2345, 2016 | 66 | 2016 |
| Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting S Meyer, M Nederend, JHM Jansen, KR Reiding, SR Jacobino, J Meeldijk, ... MAbs 8 (1), 87-98, 2016 | 52 | 2016 |
| Simultaneous targeting of FcγRs and FcαRI enhances tumor cell killing AM Brandsma, T Ten Broeke, M Nederend, LAPM Meulenbroek, ... Cancer immunology research 3 (12), 1316-1324, 2015 | 49 | 2015 |
| Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity (ADCC), and complement dependent … S Lohse, S Loew, A Kretschmer, JH Jansen, S Meyer, T Ten Broeke, ... British Journal of Haematology 181 (3), 413-417, 2018 | 39 | 2018 |
| FcRγ-chain ITAM signaling is critically required for cross-presentation of soluble antibody–antigen complexes by dendritic cells P Boross, N van Montfoort, DAC Stapels, CE Van Der Poel, C Bertens, ... The Journal of Immunology 193 (11), 5506-5514, 2014 | 37 | 2014 |
| Immune effector functions of human IgG2 antibodies against EGFR T Rösner, S Kahle, F Montenegro, HL Matlung, JHM Jansen, M Evers, ... Molecular Cancer Therapeutics 18 (1), 75-88, 2019 | 31 | 2019 |
| Inhibition of the classical and lectin pathway of the complement system by recombinant LAIR-2 MJM Olde Nordkamp, P Boross, C Yildiz, JH Jansen, JHW Leusen, ... Journal of innate immunity 6 (3), 284-292, 2014 | 28 | 2014 |
| Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo SR Jacobino, M Nederend, JF Reijneveld, D Augustijn, JHM Jansen, ... MAbs 10 (3), 453-462, 2018 | 24 | 2018 |
